Our dedicated physicians, basic scientists and staff are involved with a vast variety of cutting edge research projects, at virtually every level of interest, for the cerebellar ataxias and Friedrich's Ataxia.
In the basic science laboratories we are investigating these ataxic disorders on a cellular level to gain a better understanding of what is happening within the neurological system of these patients. Current studies include areas of:
- neuronal transmission
- neuronal receptors
- molecular medicine
There are also clinical studies evolving within the center. A very recent finding of a potential drug treatment has led to an exiting study for the ataxic patient. The initial clinical trials are underway for a select population of patients with SCA1, 2, 3 and 6.
Recognizing the limitations this movement disorder creates for the afflicted individual, we are investigating a novel therapeutic movement program. This program's design places emphasis on the unique movements and postures the ataxic person develops as their disorder progresses, then teaches basic techniques and required skills which enable the ataxic person to walk and move more normally. Preliminary results are promising and a trial clinical study is in the planning stages.
Frohna Research Initiative
- RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe
- A First in Human Study of RT001 in Patients With Friedreich's Ataxia
- An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia
- An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias
- Clinical Outcome Measures in Friedreich’s Ataxia
- Longitudinal change of gait and balance in Friedreich ataxia
- EPI-743 in Friedreich's Ataxia Point Mutations
- Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia
- Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia
- Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
- Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia